The DYRK2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the DYRK2 gene in the HeLa cell background. This cell pool offers a physiologically relevant model for studying DYRK2 kinase loss in a widely used human epithelial cell line derived from cervical adenocarcinoma. The polyclonal nature preserves genetic heterogeneity, avoiding clonal bias while enabling functional assays in a cancer-relevant context.
HeLa cells, an immortalized epithelial line from cervical adenocarcinoma, are a mainstay of biomedical research due to their robust propagation and well-mapped signaling networks. Although p53 is targeted by HPV E6 for proteasomal degradation, HeLa cells retain low-level p53 activity that can be induced by genotoxic stress, making them responsive to DNA damage pathways. This characteristic renders them ideal for examining DYRK2-dependent apoptosis and cell cycle checkpoints.
DYRK2, a dual-specificity kinase, is a pivotal effector of DNA damage signaling. Upstream kinases ATM and ATR activate DYRK2, which then phosphorylates p53 at Ser46, driving expression of pro-apoptotic genes BAX and PUMA, and cell cycle inhibitor p21. DYRK2 also phosphorylates c-Jun and cyclin D1, promoting their ubiquitin-mediated degradation and thereby restricting proliferation. Through interactions with 14-3-3, MDM2, HIPK2, and DCAF7, DYRK2 integrates cues from p53, Wnt, TGF-??, Hippo, and cell cycle pathways, coordinating apoptosis, cell cycle arrest, and differentiation.
In HeLa cells, DYRK2 knockout likely blunts p53 Ser46 phosphorylation and impairs DNA damage-triggered apoptosis, providing a tool to dissect the DYRK2?Cp53 apoptotic axis. Given the HPV E6-mediated p53 suppression, the remaining stress-responsive p53 pool is delicately balanced, and loss of DYRK2 may tip the equilibrium toward survival. Moreover, disrupted cyclin D1 degradation and c-Jun stabilization can be studied for their effects on cell cycle progression and AP-1 activity, making this model valuable for tumor suppression and drug-screening studies.
Typical assays include western blot detection of DYRK2 and phospho-p53 (Ser46), Annexin V/PI apoptosis assays, cell cycle flow cytometry, and co-immunoprecipitation of DYRK2 with p53 or 14-3-3. RT-qPCR for p21 and BAX, along with luciferase reporter assays, can quantify p53 transcriptional activity. The knockout pool is ideal for DNA damage response, kinase signaling, and cancer biology research. For additional information or custom solutions, please contact Ascent Research.
